bcl-X Protein

• 

  Subject Areas on Research

  • A GH3-like domain in reaper is required for mitochondrial localization and induction of IAP degradation. 
  • A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. 
  • A pathway of neuronal apoptosis induced by hypoxia/reoxygenation: roles of nuclear factor-kappaB and Bcl-2. 
  • Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. 
  • Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. 
  • Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. 
  • Apoptosis and B cell tolerance. 
  • Autophagy provides nutrients but can lead to Chop-dependent induction of Bim to sensitize growth factor-deprived cells to apoptosis. 
  • Bcl-xL is an oncogenic driver in colorectal cancer. 
  • CXCL12 prolongs naive CD4+ T lymphocytes survival via activation of PKA, CREB and Bcl2 and BclXl up-regulation. 
  • Calmodulin-dependent kinase IV links Toll-like receptor 4 signaling with survival pathway of activated dendritic cells. 
  • Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. 
  • Delayed myocardial preconditioning by alpha1-adrenoceptors involves inhibition of apoptosis. 
  • Diacylglycerol kinase ζ limits B cell antigen receptor-dependent activation of ERK signaling to inhibit early antibody responses. 
  • FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. 
  • Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. 
  • Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models. 
  • H/D exchange- and mass spectrometry-based strategy for the thermodynamic analysis of protein-ligand binding. 
  • Human RPE expression of cell survival factors. 
  • IL-15 regulates homeostasis and terminal maturation of NKT cells. 
  • In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. 
  • In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. 
  • In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. 
  • Inhibition of apoptotic signaling and neointimal hyperplasia by tempol and nitric oxide synthase following vascular injury. 
  • Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. 
  • Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation. 
  • Low K+ promotes NF-kappaB/DNA binding in neuronal apoptosis induced by K+ loss. 
  • Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. 
  • Modulation of cell death by Bcl-XL through caspase interaction. 
  • Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. 
  • Mutation of bcl-x gene in non-Hodgkin's lymphoma. 
  • Orphan nuclear receptors in T lymphocyte development. 
  • PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. 
  • PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. 
  • Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin- 3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation. 
  • Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. 
  • RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. 
  • Regulation of the TCRalpha repertoire by the survival window of CD4(+)CD8(+) thymocytes. 
  • Relaxed negative selection in germinal centers and impaired affinity maturation in bcl-xL transgenic mice. 
  • Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. 
  • Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity. 
  • Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. 
  • Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia. 
  • The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. 
  • The antiapoptotic protein Bcl-xL is dispensable for the development of effector and memory T lymphocytes. 
  • The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. 
  • The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. 
  • The importance of Bcl-xL in the survival of human RPE cells. 
  • The role of Bcl-xL in mouse RPE cell survival. 
  • Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. 
  • mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.